Drugs / L-5-methyltetrahydrofolate
L-5-methyltetrahydrofolate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00468481 | Apr 2007 → Aug 2008 | neural tube defect | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-5-methyltetrahydrofolate | “This study investigated the effects of adding levomefolate calcium 0.451 mg (the calcium salt of L-5-methyltetrahydrofolate; Metafolin®) to an oral contraceptive” PMID 22067790 ↗ Jul 2011 |
| Known as | L-5-MTHF | “0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)” NCT00468481 ↗ |
| Known as | levomefolate calcium | “This study investigated the effects of adding levomefolate calcium 0.451 mg (the calcium salt of L-5-methyltetrahydrofolate; Metafolin®) to an oral contraceptive” PMID 22067790 ↗ Jul 2011 |
| Known as | Metafolin | “This study investigated the effects of adding levomefolate calcium 0.451 mg (the calcium salt of L-5-methyltetrahydrofolate; Metafolin®) to an oral contraceptive” PMID 22067790 ↗ Jul 2011 |